BRPI0822989A2 - anticorpos de neutralização de citomegalovíorus humano e uso dos mesmos - Google Patents
anticorpos de neutralização de citomegalovíorus humano e uso dos mesmosInfo
- Publication number
- BRPI0822989A2 BRPI0822989A2 BRPI0822989A BRPI0822989A BRPI0822989A2 BR PI0822989 A2 BRPI0822989 A2 BR PI0822989A2 BR PI0822989 A BRPI0822989 A BR PI0822989A BR PI0822989 A BRPI0822989 A BR PI0822989A BR PI0822989 A2 BRPI0822989 A2 BR PI0822989A2
- Authority
- BR
- Brazil
- Prior art keywords
- neutralizing antibodies
- human cytomegalovirus
- cytomegalovirus neutralizing
- human
- antibodies
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2008/002683 WO2010007463A1 (en) | 2008-07-16 | 2008-07-16 | Human cytomegalovirus neutralising antibodies and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0822989A2 true BRPI0822989A2 (pt) | 2018-05-29 |
Family
ID=40430130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0822989A BRPI0822989A2 (pt) | 2008-07-16 | 2008-07-16 | anticorpos de neutralização de citomegalovíorus humano e uso dos mesmos |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP2303923B1 (pt) |
JP (1) | JP5475774B2 (pt) |
KR (3) | KR101407216B1 (pt) |
CN (1) | CN102143974B (pt) |
AU (1) | AU2008359583B2 (pt) |
BR (1) | BRPI0822989A2 (pt) |
CA (1) | CA2730620A1 (pt) |
EA (1) | EA201170204A1 (pt) |
ES (1) | ES2548014T3 (pt) |
IL (1) | IL210352A0 (pt) |
MA (1) | MA32566B1 (pt) |
MX (1) | MX2011000542A (pt) |
NZ (1) | NZ591055A (pt) |
PT (1) | PT2303923E (pt) |
TN (1) | TN2010000616A1 (pt) |
WO (1) | WO2010007463A1 (pt) |
ZA (1) | ZA201100489B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
SG10201608381SA (en) | 2008-07-16 | 2016-11-29 | Inst Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
BR112012015523A2 (pt) | 2009-12-23 | 2017-04-18 | 4-Antibody Ag | membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv. |
WO2012006369A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
LT3981427T (lt) | 2010-08-31 | 2022-08-10 | Glaxosmithkline Biologicals S.A. | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
MX363307B (es) | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Plataformas para suministro de antigenos. |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
CN102286099B (zh) * | 2011-08-05 | 2014-04-09 | 深圳市卫光生物制品股份有限公司 | 静注巨细胞病毒人免疫球蛋白及其制备方法 |
US10006096B2 (en) * | 2012-03-27 | 2018-06-26 | Variation Biotechnologies Inc. | Methods for detection of anti-cytomegalovirus neutralizing antibodies |
CN104838000B (zh) | 2012-07-27 | 2022-12-20 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
WO2014099908A1 (en) * | 2012-12-17 | 2014-06-26 | Genentech, Inc. | Methods for inhibiting viral infection in transplant patients |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN107325178A (zh) * | 2017-06-29 | 2017-11-07 | 佛山市南海区普罗圣塔生物科技有限公司 | 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用 |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
CN117098839A (zh) * | 2021-02-05 | 2023-11-21 | 美国安进公司 | 非终末抗体发现方法和单细胞测定 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
EP0248909B1 (en) * | 1985-12-06 | 1994-08-17 | Teijin Limited | Anticytomegaloviral human monoclonal antibody and process for its preparation |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
AU8063798A (en) | 1997-06-19 | 1999-01-04 | Regents Of The University Of California, The | Secretory immunoglobulin produced by single cells and methods for making and using same |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
DK2662390T3 (da) * | 2004-06-21 | 2017-11-06 | Squibb & Sons Llc | Interferon alpha receptor 1-antistoffer og anvendelse heraf |
ES2546543T3 (es) * | 2005-03-14 | 2015-09-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anticuerpos monoclonales humanos contra los virus Hendra y Nipah |
CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
GB0700133D0 (en) * | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
-
2008
- 2008-07-16 JP JP2011518016A patent/JP5475774B2/ja not_active Expired - Fee Related
- 2008-07-16 AU AU2008359583A patent/AU2008359583B2/en not_active Ceased
- 2008-07-16 CA CA2730620A patent/CA2730620A1/en not_active Abandoned
- 2008-07-16 WO PCT/IB2008/002683 patent/WO2010007463A1/en active Application Filing
- 2008-07-16 BR BRPI0822989A patent/BRPI0822989A2/pt not_active IP Right Cessation
- 2008-07-16 KR KR1020117001329A patent/KR101407216B1/ko active IP Right Grant
- 2008-07-16 CN CN200880130982.9A patent/CN102143974B/zh not_active Expired - Fee Related
- 2008-07-16 EP EP08875708.3A patent/EP2303923B1/en active Active
- 2008-07-16 EP EP15172997.7A patent/EP2960250A1/en not_active Withdrawn
- 2008-07-16 PT PT88757083T patent/PT2303923E/pt unknown
- 2008-07-16 NZ NZ591055A patent/NZ591055A/xx not_active IP Right Cessation
- 2008-07-16 MX MX2011000542A patent/MX2011000542A/es active IP Right Grant
- 2008-07-16 EA EA201170204A patent/EA201170204A1/ru unknown
- 2008-07-16 KR KR1020147006967A patent/KR20140041951A/ko not_active Application Discontinuation
- 2008-07-16 KR KR20147033802A patent/KR20150002895A/ko not_active Application Discontinuation
- 2008-07-16 ES ES08875708.3T patent/ES2548014T3/es active Active
-
2010
- 2010-12-28 TN TNP2010000616A patent/TN2010000616A1/fr unknown
- 2010-12-29 IL IL210352A patent/IL210352A0/en unknown
-
2011
- 2011-01-19 ZA ZA2011/00489A patent/ZA201100489B/en unknown
- 2011-02-15 MA MA33620A patent/MA32566B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR101407216B1 (ko) | 2014-06-16 |
NZ591055A (en) | 2012-08-31 |
EA201170204A1 (ru) | 2011-08-30 |
CN102143974B (zh) | 2015-03-25 |
AU2008359583B2 (en) | 2012-04-05 |
EP2303923B1 (en) | 2015-06-24 |
ZA201100489B (en) | 2013-03-27 |
IL210352A0 (en) | 2011-03-31 |
ES2548014T3 (es) | 2015-10-13 |
CA2730620A1 (en) | 2010-01-21 |
CN102143974A (zh) | 2011-08-03 |
AU2008359583A1 (en) | 2010-01-21 |
JP2011527899A (ja) | 2011-11-10 |
MX2011000542A (es) | 2011-08-03 |
MA32566B1 (fr) | 2011-08-01 |
TN2010000616A1 (en) | 2012-05-24 |
PT2303923E (pt) | 2015-08-25 |
KR20150002895A (ko) | 2015-01-07 |
WO2010007463A1 (en) | 2010-01-21 |
KR20110055517A (ko) | 2011-05-25 |
KR20140041951A (ko) | 2014-04-04 |
EP2960250A1 (en) | 2015-12-30 |
EP2303923A1 (en) | 2011-04-06 |
JP5475774B2 (ja) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0916443A2 (pt) | anticorpos de neutralização de citomegalovírus humanos e uso dos mesmos | |
BRPI0822989A2 (pt) | anticorpos de neutralização de citomegalovíorus humano e uso dos mesmos | |
BRPI0819909A2 (pt) | anticorpos antimesotelina e usos dos mesmos | |
BRPI0912198A2 (pt) | anticorpos anti-fn14 e usos dos mesmos | |
BRPI1014544A8 (pt) | anticorpos anti-il-17f e metodos de uso dos mesmos | |
BRPI1010024A2 (pt) | derivados de aminopirrolidinona e uso dos mesmos | |
BRPI0922708A2 (pt) | peptídeos mini-hepcidina e métodos de uso do mesmo | |
BRPI0813514A2 (pt) | anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso | |
BRPI1009455A2 (pt) | anticorpos anti-c40 e usos dos mesmos | |
BRPI0917888A2 (pt) | Formulação de anticorpo líquida estável | |
BR112012003661A2 (pt) | "compostos de biarila e métodos de uso dos mesmos." | |
BR112012004731A2 (pt) | peptídeos derivados de wnt10 e uso dos mesmos | |
BRPI0821658A2 (pt) | Anticorpos contra nkg2d humano e usos dos mesmos | |
BR112012004710A2 (pt) | imunoglobulinas de domínio variável duplo e uso das mesmas | |
BRPI0816835A2 (pt) | dispositivo de pulverização e método de uso do mesmo | |
BRPI0920927A2 (pt) | derivados de azaquinolinona e usos dos mesmos | |
BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
BR112013014321A2 (pt) | moduladores inovadores e métodos de uso | |
BRPI0913656A2 (pt) | anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos | |
BR112012001260A2 (pt) | conjugados de epsilon-polilisina e o emprego dos mesmos | |
BRPI0909954A2 (pt) | "diazacarbazóis e métodos de uso" | |
BR112012018329A2 (pt) | agentes de coloração e métodos de uso destes | |
BRPI0914839A2 (pt) | uso de copolímeros anfotéricos solúveis em água | |
BRPI0907236A2 (pt) | inibidores de proteína quinase e uso dos mesmos | |
BRPI1012097A2 (pt) | antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: INSTITUTE FOR RESEARCH IN BIOMEDICINE (CH) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2474 DE 05-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |